Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alrizomadlin in BAP1 Cancer Syndrome and Early-Stage Mesothelioma
NCT06654050Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Mar 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alrizomadlin in mesothelioma, BAP1 tumor predisposition syndrome (BAP1-TPDS), sponsored by National Cancer Institute. Planned start Mar 2026; status: withdrawn.
02
Drugs
alrizomadlin
03
Conditions
mesotheliomaBAP1 tumor predisposition syndrome (BAP1-TPDS)
Beyond the preview
Go deeper on NCT06654050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654050.